Together, this evidence underscores the pivotal role of FAP as a prognostic biomarker associated with unfavorable treatment responses in ccRCC, emphasizing the importance of considering this biomarker in shaping precision medicine strategies for this disease [16, 18]. The gene discussed is FAP; the disease is nonpapillary renal cell carcinoma.